Mayo Clinic, Rochester, Minnesota.
J Urol. 2019 Sep;202(3):599-610. doi: 10.1097/JU.0000000000000245. Epub 2019 Aug 8.
Current penile traction therapy devices have significant limitations, including the need to use them for 3 to 8 hours per day. Given these issues, the novel RestoreX® penile traction therapy device was developed in cooperation with Mayo Clinic.
We performed a randomized, controlled, single-blind, intent to treat trial (ClinicalTrials.gov NCT03389854) in men with Peyronie's disease who were assigned to the penile traction therapy device for 30 to 90 minutes per day or to no therapy for 3 months. Study inclusion criteria were curvature 30 degrees or greater with no study exclusions due to complex curvature, hourglass deformity, prior Peyronie's disease therapy or surgery, or calcification. The primary outcome was safety and secondary outcomes were penile length and curvature, and questionnaire responses.
A total of 110 men were randomized 3:1 to the penile traction therapy group or the control group. The cohorts were well matched with a mean age of 58.4 years, a 49.7-month Peyronie's disease history and 59.3 degree curvature. Overall penile traction therapy was well tolerated with only transient and mild adverse events reported. At 3 months men undergoing penile traction therapy demonstrated significant improvements over controls in penile length (1.5 vs 0 cm, p <0.001), curvature (-11.7 vs 1.3 degrees, p <0.01) and erectile function (4.3 vs -0.7, p = 0.01) according to the International Index of Erectile Function-Erectile Function among men with erectile dysfunction. Overall 77% of the men on penile traction therapy experienced improved curvature (mean -17.2 degrees in 28.2% of responders) while 94% achieved increased length (1.6 cm in 10.9%). Counter bending and the white line indicator improved efficacy, validating key device innovations. Of men who had previously used other penile traction therapy devices 100% preferred the RestoreX device.
Penile traction therapy with the RestoreX device for 30 to 90 minutes per day was safe, and resulted in significant and clinically meaningful improvements in penile curvature and length in men with Peyronie's disease, and in erectile function in men with erectile dysfunction and Peyronie's disease with no significant adverse events. To our knowledge these data represent the only reported improvements for any device used less than 3 to 8 hours per day.
目前的阴茎牵引治疗设备存在显著的局限性,包括每天需要使用 3 至 8 小时。鉴于这些问题,新型 RestoreX®阴茎牵引治疗设备与梅奥诊所合作开发。
我们对患有 Peyronie 病的男性进行了一项随机、对照、单盲、意向治疗试验(ClinicalTrials.gov NCT03389854),这些男性被分配到每天使用阴茎牵引治疗设备 30 至 90 分钟,或不进行治疗 3 个月。研究纳入标准为曲率 30 度或以上,由于复杂曲率、沙漏变形、既往 Peyronie 病治疗或手术或钙化,没有研究排除。主要结局是安全性,次要结局是阴茎长度和曲率以及问卷应答。
共有 110 名男性被随机分为 3:1 接受阴茎牵引治疗组或对照组。两组队列的平均年龄为 58.4 岁,Peyronie 病病史为 49.7 个月,曲率为 59.3 度,匹配良好。总体而言,阴茎牵引治疗耐受性良好,仅报告了短暂和轻度的不良事件。3 个月时,接受阴茎牵引治疗的男性在阴茎长度(1.5 比 0 cm,p<0.001)、曲率(-11.7 比 1.3 度,p<0.01)和勃起功能(4.3 比-0.7,p=0.01)方面均优于对照组,根据国际勃起功能指数-勃起功能障碍男性的勃起功能。总体而言,77%的阴茎牵引治疗男性的曲率得到改善(28.2%的应答者平均-17.2 度),94%的男性长度增加(1.6 cm,10.9%)。反向弯曲和白线指标提高了疗效,验证了关键的设备创新。在以前使用过其他阴茎牵引治疗设备的男性中,100%的人更喜欢 RestoreX 设备。
每天使用 RestoreX 设备进行 30 至 90 分钟的阴茎牵引治疗是安全的,可显著改善男性 Peyronie 病的阴茎曲率和长度,以及男性勃起功能障碍和 Peyronie 病的勃起功能,且无显著不良事件。据我们所知,这些数据是唯一报告的任何设备每天使用少于 3 至 8 小时的改善数据。